Dr. Reddy's Laboratories recalls bottles of generic Nexium on quality concerns

drugs
Dr. Reddy's previously pulled lots of generic esomeprazole off shelves on quality concerns. (Pixabay)

Indian drugmaker Dr. Reddy's Laboratories has had its share of run-ins with the FDA over manufacturing problems at a suite of its facilities. Now, the company is pulling bottles of a generic heartburn med off shelves––for the second time in as many years––after failed quality testing. 

Dr. Reddy's has voluntarily recalled 1,752 bottles of generic esomeprazole magnesium after tested lots showed discoloration and contained brown pellets, according to the FDA. 

In late April, Dr. Reddy's launched the recall for 1,000-count bottles produced at its facility in Bachupally in Telangana, India. The drugmaker recalled 40,592 bottles of the same product produced at Bachupally back in February 2019, the FDA said. 

The Indian drugmaker's lasting problems with the generic heartburn med continue a series of run-ins with the FDA over the past few years. 

RELATED: Dr. Reddy's sterile plant now meets at least minimal compliance, FDA says

In February, Dr. Reddy’s reported (PDF) that issues outlined in an eight-observation Form 483 last August for its formulations facility in Duvvada, an area of Visakhapatnam in India, had been deemed "voluntary action initiated" by the agency. 

That limited stamp of approval was a big step up for the drugmaker, which had at least a dozen Form 483s issued for its facilities since 2017, including one so far this year. 

The Duvvada plant concerns followed a 2015 warning letter in which the FDA cited three of the company's Indian plants. 

RELATED: Need a safe antacid for heartburn? FDA declares Pepcid, Nexium and others free of NDMA

Suggested Articles

Lupin Pharmaceuticals has shut down an Indian generics plant after 18 workers tested positive for COVID-19, Reuters reported.

Merck KGaA could see billions of dollars in revenue opportunity as it assists certain players with their COVID-19 scale-up, an analyst says. 

The FDA approved Johnson & Johnson's Tremfya as the first IL-23 inhibitor to treat psoriatic arthritis, joining a suite of immunology blockbusters.